Novo Seeds invests millions in Belgian cancer company
Brussels-based biotech company Camel-IDS has raised EUR 37 million (USD 41.83 million) to continue the development of the phase I candidate against an especially aggressive form of breast cancer. Danish Novo Seeds is among the lead investors.
The competition is increasing on the breast cancer market, which is potentially worth billions of dollars. Now, Danish holding and investment company Novo Holdings intensifies this competition.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
.jpg)
